Stock LSB LAKESHORE BIOPHARMA CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

LakeShore Biopharma Co., Ltd Stock

Equities

LSB

KYG9845F1090

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
0.6977 USD +0.93% Intraday chart for LakeShore Biopharma Co., Ltd -8.20% +36.54%
Jun. 10 Lakeshore Biopharma Co., Ltd Announces Executive Changes CI
May. 28 YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS CI

Financials

Sales 2024 * 596M 82.17M Sales 2025 * 827M 114M Capitalization 953M 131M
Net income 2024 * -297M -40.93M Net income 2025 * -122M -16.81M EV / Sales 2024 * 1.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.15 x
P/E ratio 2024 *
-1.59 x
P/E ratio 2025 *
-4.64 x
Employees 773
Yield 2024 *
-
Yield 2025 *
-
Free-Float 18.57%
More Fundamentals * Assessed data

Chart LakeShore Biopharma Co., Ltd

Dynamic Chart

Latest news about LakeShore Biopharma Co., Ltd

Lakeshore Biopharma Co., Ltd Announces Executive Changes CI
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS CI
YS Biopharma to Become LakeShore Biopharma, Ticker Symbol to Change to LSB From YS Starting May 28 MT
YS Biopharma Co., Ltd. Approves Board Appointments CI
YS Biopharma Co., Ltd. has Changed its Name to LakeShore Biopharma Co., Ltd CI
Ys Biopharma Co., Ltd Announces Executive Changes CI
YS Biopharma Co., Ltd. Approves the Appointment of Hui Shao as the Chief Business Officer CI
YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 CI
YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment MT
YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine CI
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of Pika Rabies Vaccine CI
YS Biopharma Co., Ltd. Announces Board Changes CI
YS Biopharma Co., Ltd. Announces Board Changes CI
YS Biopharma Co Announces the Results of Extraordinary General Meeting CI
YS Biopharma Co., Ltd. Announces Board Resignations CI
More news

Analyst Recommendations on LakeShore Biopharma Co., Ltd

Noble Capital Initiates YS Biopharma With Outperform Rating, $5.25 Price Target MT
More recommendations

Press releases LakeShore Biopharma Co., Ltd

LakeShore Biopharma : Departure of Directors Form 6 K PU
YS Biopharma Announces Name Change to LakeShore Biopharma PR
YS Biopharma Announces Results of Extraordinary General Meeting PR
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer PR
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR
More press releases

Quotes and Performance

1 day+0.93%
1 week-8.20%
Current month-16.44%
1 month-26.57%
3 months-3.50%
6 months+43.38%
Current year+36.54%
More quotes

Highs and lows

1 week
0.68
Extreme 0.68
0.75
1 month
0.68
Extreme 0.68
1.12
Current year
0.35
Extreme 0.3503
1.12
1 year
0.35
Extreme 0.3503
1.75
3 years
0.35
Extreme 0.3503
12.93
5 years
0.35
Extreme 0.3503
12.93
10 years
0.35
Extreme 0.3503
12.93
More quotes

Managers and Directors - LakeShore Biopharma Co., Ltd

Managers TitleAgeSince
Hui Shao CEO
 Chief Executive Officer 55 20-12-30
Chun Yuan Wu DFI
 Director of Finance/CFO 46 20-12-30
Zenaida Mojares CTO
 Chief Tech/Sci/R&D Officer 65 21-12-31
Members of the board TitleAgeSince
Viren Mehta BRD
 Director/Board Member 74 -
Hui Shao CEO
 Chief Executive Officer 55 20-12-30
Ajit Shetty CHM
 Chairman 77 20-12-31
More insiders

Quotes

Date Price Change Volume
24-06-14 0.6977 +0.93% 19,496
24-06-13 0.6913 -4.12% 45,365
24-06-12 0.721 -3.74% 23,351
24-06-11 0.749 +10.15% 42,073
24-06-10 0.68 -10.53% 69,582

Delayed Quote Nasdaq, June 14, 2024 at 04:30 pm EDT

More quotes

Company Profile

LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Sector
Pharmaceuticals
Calendar
2024-08-12 - Q1 2025 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.062 CNY
Average target price
29.98 CNY
Spread / Average Target
+492.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
LAKESHORE BIOPHARMA CO., LTD Stock LakeShore Biopharma Co., Ltd
+36.54% 131M
CSL LIMITED Stock CSL Limited
+0.75% 92.38B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.03% 37.9B
BIOGEN INC. Stock Biogen Inc.
-10.46% 33.73B
UCB Stock UCB
+73.83% 27.98B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.39% 15.86B
INCYTE CORPORATION Stock Incyte Corporation
-1.08% 13.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.15% 11.67B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+169.04% 10.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-50.19% 10.04B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. LSB Stock